Viyash Scientific Limited
NSE: VIYASHPharmaceuticals
Share price
₹234.06
-0.76% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
66
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹10,182 Cr
P/E ratio
45.9
P/B ratio
3.5
ROCE
13.4%
ROE
7.4%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Our sales figures for this company step up at Jun 2013 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
Our sales figures for this company step up at Jun 2013 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 0.6 times its growth rate, on earnings growth of 73%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Viyash Scientific Limited — this one | 73%/yr | 45.9× | ₹0.63 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.1× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 79.4× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.2× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 100.5× | ₹25.1 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 71 of 130 on returns, 40 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 13.4% on capital, ahead of 45% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹747 crore of cash from the business and spent ₹304 crore on plant and equipment, with ₹443 crore to spare; it still raised ₹62 crore mostly borrowed — borrowings rose from ₹365 crore to ₹490 crore. And the profit is real: of every 100 rupees it reported over 12 years, about 145 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 54 days for its cash to waiting 111 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue up 20% and profit margin at 21.6%, ahead of the 20% promised in February
Announced 11 Aug 2026 · Consolidated · Unaudited
Revenue
₹946 Cr
Revenue vs last year
+114.6%
Revenue vs last quarter
+2.9%
Net profit
₹79 Cr
Profit vs last year
+340.5%
Profit vs last quarter
+20.1%
Net margin
8.4%
EPS
₹1.51
Earnings call transcript · 12 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹10,182 Cr
- Prev close
- ₹234.06
- 52w High
- ₹298
- 52w Low
- ₹178
- Enterprise value
- ₹10,402 Cr
- Beta
- 1.4
- Price CAGR 1y
- 12.0%
- Price CAGR 3y
- 37.0%
- Price CAGR 5y
- 3.0%
- Price CAGR 10y
- 7.0%
Ratios
- Return on assets
- 4.9%
- PEG ratio
- 0.6
- P/E ratio
- 45.9
- P/B ratio
- 3.5
- EV / EBITDA
- 14.6
- Industry P/E
- 37.6
- ROCE
- 13.4%
- ROCE 5y average
- 4.8%
- ROE
- 7.4%
- Debt / Equity
- 0.2
- Interest coverage
- 6.1
- Dividend yield
- 0.0%
- ROE 3y average
- 4.0%
- ROE last year
- 7.0%
Annual P&L
- Annual revenue
- ₹3,420 Cr
- Annual profit
- ₹225 Cr
- Operating margin
- 19.0%
- Net profit margin
- 6.6%
- EBITDA margin
- 19.1%
- Sales growth 3y
- 34.0%
- Sales growth 5y
- 20.2%
- Profit growth 3y
- 73.0%
- Profit growth 5y
- 15.0%
- EPS
- ₹4.1
- Sales growth TTM
- 53.0%
- Profit growth TTM
- 148.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹946 Cr
- Profit latest quarter
- ₹79 Cr
- YoY quarterly sales growth
- 19.5%
- YoY quarterly profit growth
- 113.5%
- OPM latest quarter
- 18.9%
Balance Sheet
- Book Value
- ₹66.9
- Face Value
- ₹2.0
- Total debt
- ₹490 Cr
- Total cash
- ₹270 Cr
- Borrowings
- ₹490 Cr
- Reserves / Equity
- 32.5
Cash Flow
- Operating cash flow
- ₹323 Cr
- Free cash flow
- ₹225 Cr
- FCF yield
- 1.5%
- Net cash flow
- ₹115 Cr
Shareholding
- Promoter holding
- 61.3%
- FII holding
- 4.5%
- DII holding
- 3.8%
- Public holding
- 30.3%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,749.70 | 33.1 | 4,19,812 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,361.00 | 83.4 | 2,48,505 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,594.75 | 78.3 | 1,74,770 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,115.85 | 22.9 | 1,11,306 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,002.45 | 99.0 | 1,08,195 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,296.80 | 29.3 | 1,04,765 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Dr Reddy's Labs | 1,175.60 | 30.5 | 98,125 | 0.67 | 435.6 | -68.7 | 8,099.8 | -5.5 | 13.0 |
| Viyash Scientific | 235.55 | 46.9 | 10,403 | 0.00 | 79.3 | 103.6 | 946.4 | 19.5 | 13.4 |
| Median | 414.25 | 34.0 | 2,117 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 333 | 346 | 329 | 361 | 390 | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 |
| Expenses | 341 | 331 | 307 | 329 | 348 | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 |
| Material Cost | 159 | 180 | 183 | 347 | 364 | 402 | |||||||
| Change in Inventories | 4.14 | 2.76 | -15 | -13 | -43 | -33 | |||||||
| Purchases of Stock-in-Trade | 37 | 52 | 45 | 57 | 92 | 65 | |||||||
| Employee Cost | 77 | 79 | 82 | 138 | 150 | 163 | |||||||
| Other Expenses | 79 | 76 | 74 | 154 | 173 | 171 | |||||||
| Operating Profit | -8 | 15 | 22 | 32 | 42 | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 |
| OPM % | -2.47 | 4.37 | 6.76 | 8.93 | 11 | 11 | 13 | 12 | 15 | 20 | 20 | 20 | 19 |
| Other Income | -23 | 10 | 7 | -1 | 3 | 0 | 4 | 1 | 6 | 6 | -27 | 16 | 8 |
| Exceptional items (within Other Income) | -0.34 | -1.25 | -1.70 | -41 | 0 | 0 | |||||||
| Interest | 10 | 13 | 13 | 12 | 16 | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 |
| Profit before tax | -56 | -3 | 1 | 3 | 12 | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 |
| Tax % | -38 | 123 | -617 | 52 | 24 | 20 | -71 | 36 | 24 | 29 | 34 | 47 | 29 |
| Net Profit | -35 | -7 | 11 | 1 | 9 | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 |
| EPS in Rs | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 |
| Diluted EPS in Rs | 0.36 | 0.56 | 0.58 | 0.87 | 1.17 | 1.47 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 3,007 | 3,420 | 3,575 |
| Expenses | 425 | 550 | 641 | 765 | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,308 | 2,620 | 2,768 | 2,864 |
| Material Cost | 617 | 1,377 | |||||||||||
| Change in Inventories | -18 | -65 | |||||||||||
| Purchases of Stock-in-Trade | 213 | 251 | |||||||||||
| Employee Cost | 281 | 566 | |||||||||||
| Other Expenses | 297 | 640 | |||||||||||
| Operating Profit | 18 | 56 | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 61 | 387 | 653 | 711 |
| OPM % | 4.20 | 9 | 6 | 10 | 12 | 14 | 16 | 8 | 0.80 | 4.50 | 13 | 19 | 20 |
| Other Income | 48 | 14 | 9 | 436 | 9 | 10 | -0 | 11 | -58 | -6 | -49 | -1 | 3 |
| Exceptional items (within Other Income) | -4.97 | -44 | |||||||||||
| Interest | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 | 86 | 69 | 61 |
| Depreciation | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 | 239 | 234 | 240 |
| Profit before tax | -8 | -14 | -17 | 444 | 59 | 94 | 137 | 53 | -138 | -55 | 13 | 349 | 413 |
| Tax % | 40 | 19 | -3 | 3 | 3 | 13 | 24 | 15 | -11 | -46 | -20 | 36 | |
| Net Profit | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -30 | 16 | 225 | 267 |
| EPS in Rs | -0.70 | -0.78 | -0.57 | 17 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -1.44 | 0.93 | 4.06 | 5.76 |
| Diluted EPS in Rs | 0.85 | 4.01 | |||||||||||
| Dividend Payout % | 0 | 0 | 0 | 1 | 10 | 0 | 13 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 19%
- 5 years
- 20%
- 3 years
- 34%
- TTM
- 53%
Compounded profit growth
- 10 years
- 28%
- 5 years
- 15%
- 3 years
- 73%
- TTM
- 148%
Stock price CAGR
- 10 years
- 7%
- 5 years
- 3%
- 3 years
- 37%
- 1 year
- 12%
Return on equity
- 10 years
- 8%
- 5 years
- 3%
- 3 years
- 4%
- Last year
- 7%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 | 87 |
| Reserves | 61 | 898 | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 607 | 2,382 | 2,824 |
| Borrowings | 473 | 312 | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 488 | 654 | 490 |
| Other Liabilities | 343 | 265 | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 389 | 1,042 | 1,195 |
| Minority Interest | 204 | |||||||||||
| Total Liabilities | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 4,128 | 4,596 |
| Fixed Assets | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 2,103 | 2,103 |
| CWIP | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 43 | 70 |
| Investments | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 0 | 0 |
| Other Assets | 336 | 485 | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 922 | 1,981 | 2,422 |
| Total Assets | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 4,128 | 4,596 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -24 | -0 | -7 | 45 | 116 | 115 | 115 | 31 | 17 | 31 | 345 | 323 |
| Cash from Investing Activity | -157 | -310 | -116 | 7 | -68 | -72 | 10 | -94 | -65 | -6 | -448 | -84 |
| Cash from Financing Activity | 179 | 309 | 147 | -57 | -20 | -43 | -139 | 67 | 32 | -1 | 87 | -123 |
| Net Cash Flow | -1 | -2 | 24 | -5 | 28 | 0 | -14 | 4 | -16 | 23 | -16 | 115 |
| Free Cash Flow | -137 | -63 | -82 | 0 | 92 | 75 | 70 | -1 | -58 | 19 | 258 | 225 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 116 | 136 | 111 | 98 | 99 | 93 | 85 | 88 | 89 | 98 | 112 |
| Inventory Days | 153 | 164 | 165 | 125 | 134 | 132 | 139 | 160 | 152 | 166 | 169 | 188 |
| Days Payable | 147 | 175 | 208 | 127 | 141 | 133 | 119 | 119 | 107 | 121 | 121 | 140 |
| Cash Conversion Cycle | 101 | 105 | 93 | 110 | 92 | 98 | 112 | 126 | 132 | 135 | 146 | 160 |
| Working Capital Days | -111 | 65 | -25 | 20 | 33 | 29 | 51 | 54 | 46 | 30 | 74 | 111 |
| ROCE % | 8 | 2 | 1 | 40 | 9 | 12 | 16 | 6 | -3 | 0 | 8 | 13 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
220inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Viyash Scientific Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- packing materials
- pharmaceutical raw materials and key starting materials (KSM/intermediates)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE807F01027
Plants
- Viyash Ambernath formulation facility
- Viyash Brazil facility
- Viyash Mahad API facility
- Viyash Spain API facility
- Viyash Turkey API facility
- Viyash Visakhapatnam veterinary API facility
News impact
Big market events that reach Viyash Scientific Limited, and how the effect spreads.
26 Sept, 23:54 IST · Market event · high impact
Zydus Lifesciences’ New Jersey facility clears USFDA inspection with nil observations
Zydus Lifesciences cleared a US drug-safety inspection in New Jersey with no observations, lifting Zydus shares while rival drug makers see little direct effect.
Who it hits first
- Zydus Lifesciences, the Ahmedabad-based drug maker, had its New Jersey site's drug-safety monitoring system inspected by the US Food and Drug Administration from September 22 to 25.
- The inspection closed with nil (zero) observations, meaning the inspectors found no problems needing corrective action.
- This removes a near-term regulatory worry for Zydus's US business but does not by itself create new sales.
Who may gain
- Zydus Lifesciences — lower US regulatory risk and steadier sentiment for its existing US drug sales.
- Zydus shareholders — reduced overhang of a warning letter or import restriction at this New Jersey site.
Along the supply chain
Downstream
US distributors, pharmacies and patients see continued supply confidence, but no price or volume shift — this clearance does not approve a new drug.
Upstream
Ingredient, packaging and service suppliers to Zydus see no direct order change — a clean safety-system inspection keeps existing production running rather than adding new volume.
Where demand moves
Business
No new purchase orders flow from this clearance — it is a compliance pass, not a contract win — but it protects Zydus's existing US drug sales from disruption.
Capital
Investors are likely to give Zydus a small relief premium as US regulatory risk falls, with little fresh money moving into rival drug stocks on this news alone.
How it spreads across sectors
Healthcare
Mild positive sentiment for Indian drug exporters on clean USFDA news, but no sector-wide earnings change since the clearance is specific to one Zydus site.
When it plays out
Immediate
1-7 days: Zydus shares firm modestly on relief; rival drug stocks barely move.
Medium term
1-6 months: no lasting uplift unless followed by new US approvals or launches linked to the site.
Short term
1-4 weeks: focus shifts back to Zydus's US pipeline and pricing; the inspection fades as a price driver.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 8 Sep 2021 | unspecified | ₹0.5 |
|---|---|---|
| 21 Aug 2019 | unspecified | ₹0.2 |
| 20 Nov 2017 | interim | ₹0.2 |
Splits, bonuses & buybacks
- daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 26 Aug 2026 | CA HULL INVESTMENTS | SELL | 1,22,64,022 | ₹265.44 |
| 26 Aug 2026 | CA HARBOR INVESTMENTS | SELL | 1,18,60,493 | ₹263.24 |
| 26 Aug 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | SELL | 99,77,062 | ₹266.77 |
| 26 Aug 2026 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | BUY | 98,07,102 | ₹264.68 |
| 26 Aug 2026 | CA HULL INVESTMENTS | SELL | 93,02,182 | ₹263.36 |
| 26 Aug 2026 | CA HARBOR INVESTMENTS | SELL | 85,40,003 | ₹265.40 |
| 26 Aug 2026 | F3 ADVISORS PRIVATE LIMITED | SELL | 49,58,965 | ₹264.26 |
| 26 Aug 2026 | F3 ADVISORS PRIVATE LIMITED | BUY | 48,74,466 | ₹265.12 |
| 26 Aug 2026 | NEO APEX SHARE BROKING SERVICES LLP | SELL | 41,63,047 | ₹266.16 |
| 26 Aug 2026 | NEO APEX SHARE BROKING SERVICES LLP | BUY | 41,63,047 | ₹264.70 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call15 Aug 2026
- Earnings call · Q1FY2712 Aug 2026
- Annual report · 2025-2617 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q3FY266 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.